RUNX1T1 Antibody

1. RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation. Over 90% of the 175 patients who were in continuous complete remission had a >/=3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a >/=4-log reduction at >/=12 months. PMID: 28166825
2. The data suggest that the tumor suppressor activity of both RUNX1t1 and TFF1 are mechanistically connected to CEBPB and that cross-regulation between CEBPB-RUNX1t1-TFF1 plays an important role in gastric carcinogenesis. PMID: 27522676
3. The role of RUNX1T1 in t(8;21) acute myeloid leukemia and miRNA expression regulation PMID: 28322996
4. Our data revealed a novel role for RUNX1T1 as a tumor-suppressor gene in colorectal cancer through modulation of multiple cellular pathways affecting the cell cycle, DNA damage, DNA replication, estrogen signaling, and drug resistance PMID: 27798886
5. A substantial fraction of AML1-ETO/p300 co-localization occurs near TSSs in promoter regions associated with transcriptionally active loci. PMID: 25928846
6. A reduction in KIT mRNA levels was also observed in AE-silenced cells, but silencing KIT expression reduced cell growth but did not induce apoptosis. PMID: 24727677
7. RUNX1T1 gene may participate in t(8;21)(q22;q22)-dependent leukemic transformation due to its multiple interactions in cell regulatory network particularly through synergistic or antagonistic effects in relation to activity of RUNX1-RUNX1T1 fusion gene. PMID: 24976338
8. Runx1t1 epigenetically regulates the proliferation and nitric oxide production of microglia. PMID: 24586690
9. The cooperative effect of the expression of mutated KIT and AML1-ETO oncogenes is crucial for selective toxic action of binase on malignant cells. PMID: 22101339
10. RUNX1T1 point mutation may be rare and passenger mutations in acute leukemias, lung and breast cancers PMID: 21571369
11. SMAD4 knockdown accelerated this re-silencing process, suggesting that normal TGF-beta signaling is essential for the maintenance of RunX1T1 expression PMID: 21540640
12. Data show that low RUNX1T1 expression was highly associated with hepatic metastases. PMID: 21499216
13. Elevated levels of AES mRNA and protein were confirmed in AML1/ETO-expressing leukemia cells, as well as in other acute myeloid leukemia specimens. PMID: 21245488
14. ETO nervy homology region (NHR) 3 domain-PKA(RIIalpha) protein interaction does not appear to significantly contribute to AML1-ETO's ability to induce leukemia. PMID: 20708017
15. The critical role for an evolutionary conserved GATA binding site in transcriptional regulation of the ETO gene in cells of erythroid/megakaryocytic potential. PMID: 20487545
16. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells. PMID: 20090777
17. no conclusive evidence as yet that the AML1/ETO chimeric gene is sufficient per se to induce leukemia. PMID: 11869944
18. Analysis of nuclear distribution of the AML1/ETO protein and its homology domains led to identification of domains in ETO responsible for intranuclear transport and subnuclear distribution of AML1/ETO. PMID: 11983111
19. 2 independent subnuclear targeting signals in the N- and C-terminal regions of ETO direct ETO to the same binding sites occupied by AML1ETO. This provides a molecular basis for aberrant subnuclear targeting of AML1ETO, the defect in t(8;21)-related AML. PMID: 12427969
20. ETO rearrangements leading to the AML1-ETO fusion gene are frequently the result of small hidden interstitial insertions. PMID: 12557226
21. Data identify ETO as a partner for Gfi-1 and Gfi-1B, and suggest that Gfi-1 proteins repress transcription through recruitment of histone deacetylase-containing complexes. PMID: 12874834
22. ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematologic malignancies. PMID: 14551142
23. RT-PCR for the detection of AML1/ETO in children with acute non-lymphoid leukemia (ANLL) was quick, convenient and sensitive, and could be regarded as a useful method for the diagnosis and prognosis of ANLL. PMID: 14751048
24. cloning, expression, purification and crystallization of NHR3 domain PMID: 15295650
25. These findings suggest a central role of RUNX1-CBFA2T1 in the maintenance of the leukaemia. PMID: 15298716
26. N-CoR utilizes repression domains I and III for interaction and co-repression with ETO PMID: 15377655
27. DiffeRential expression of the ETO homologues suggests that they may have a potential role in hematopoietic differentiation. PMID: 15676213
28. Alternative splicing in the AML1-MTG8 fusion gene occurs in leukemia cell lines as well as in cells of leukemia paatients with a(8;21) translocation. PMID: 15723339
29. Translocations in acute myeloid leukemia (AML) is the t(8;21) is characterized by AML1-MTG8 (ETO) mutation. PMID: 16502583
30. AML1T1, an alternatively spliced isoform of the t(8;21) transcript, promotes leukemogenesis. PMID: 16892037
31. The leukemia-associated fusion protein AML1-ETO could aberrantly transactivate the EEN gene through an AML1 binding site. PMID: 16990610
32. As a result, we identified 14 unique proteins deregulated in AML1-ETO-carrying leukemic cells, including 3 up-regulated such as hairy and enhancer of split 5 (HES5) and 11 down-regulated such as MAT1 (menage a trois-1. PMID: 17058450
33. AML1/ETO participates in a protein complex with the RA receptor alpha (RARalpha) at RA regulatory regions on RARbeta2. PMID: 17244680
34. Loss of p21(WAF1) facilitates AML1-ETO-induced leukemogenesis. PMID: 17284535
35. Isoform AML1/ETO9a was correlated to acute myeloid leukemia-M2 subtype. PMID: 17649722
36. Our study suggests that KIT activating mutations in AML with t(8; 21) are associated with diminished CD 19 and positive CD56 expression on leukemic blasts and, thus, can be phenotypically distinguished from AML1-ETO leukemias PMID: 17875504
37. MTG8/ETO and Mtg16 (ETO2) associated with TCF4 PMID: 18039847
38. These results demonstrate that scl is an important mediator of the ability of AML1-ETO to reprogram hematopoietic cell fate decisions, suggesting that scl may be an important contributor to AML1-ETO-associated leukemia. PMID: 18156164
39. The interaction between SIN3B and ETO required an intact amino-terminus of ETO and the NHR2 domain. PMID: 18205948
40. Knockdown of TLE1 or TLE4 levels increased the rate of cell division of the AML1-ETO-expressing Kasumi-1 cell line, whereas forced expression of either TLE1 or TLE4 caused apoptosis and cell death. PMID: 18258796
41. ETO family member-mediated oligomerization and repression can be distinct events and that interaction between ETO family members and hSIN3B or N-CoR may not necessarily strengthen transcriptional repression. PMID: 18586123
42. the crucial role of the NHR4 domain in determination of cellular fate during AML1-ETO-associated leukemogenesis. PMID: 18952841
43. a major role for the functional interaction of AML1/ETO with AML1 and HEB in transcriptional regulation determined by the fusion protein. PMID: 19043539
44. Four copies of RUNX1T1 were found. PMID: 19100510
45. Data show that E proteins contain another conserved ETO-interacting region, termed DES, and that differential associations with AD1 and DES allow ETO to repress transcription through both chromatin-dependent and chromatin-independent mechanisms. PMID: 19289505

Show More

Hide All

HGNC: 1535

OMIM: 133435

KEGG: hsa:862

STRING: 9606.ENSP00000402257

UniGene: Hs.368431